Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
COX-2/15-LOX Inhibitor
COX-2/15-LOX-IN-5 is a potent dual inhibitor of cyclooxygenase-2 (COX-2) and 15-lipoxygenase (15-LOX). This compound effectively attenuates lipopolysaccharide-induced NF-κB activation in RAW 264.7 macrophages, highlighting its role in modulating inflammatory responses. COX-2/15-LOX-IN-5 exhibits significant anti-inflammatory and antioxidant properties, making it a valuable tool for research into inflammatory diseases and other related biological processes. -
COX-2/TAK1-NF-κB Inhibitor
BPD is a selective inhibitor of COX-2 and TAK1-NF-κB, exhibiting an IC50 of 18.5 μM for COX-2. This compound effectively reduces the transcriptional expression of key pro-inflammatory cytokines, including iNOS, TNF-α, IL-6, and IL-1β, thereby demonstrating notable anti-inflammatory properties. BPD has been shown to inhibit carrageenan-induced paw edema and mitigate LPS-induced septic mortality, making it a valuable tool for research in inflammation and related pathways. -
NF-κB/COX Inhibitor
Methoxycoronarin D is a potent inhibitor of NF-κB, demonstrating an IC50 value of 7.3 μM. Additionally, it selectively inhibits cyclooxygenase-1 (COX-1), with an IC50 value of 0.9 μM. This compound is relevant for research applications focused on inflammation and cancer due to its ability to modulate critical signaling pathways. -
COX-2 Inhibitor
Cavidine is a selective COX-2 inhibitor that exhibits potent anti-inflammatory properties. It is particularly useful in research concerning skin injuries, hepatitis, cholecystitis, and scabies. Additionally, Cavidine has been shown to alleviate LPS-induced acute lung injury through modulation of the NF-κB signaling pathway, making it a valuable compound for studying inflammation-related conditions. -
Sphingomyelinase Inhibitor, K-Ras Inhibitor, H-Ras Inhibitor, NF-κB Inhibitor
Avicin G is a potent inhibitor of sphingomyelinases, specifically targeting neutral sphingomyelinases (SMPD2/3) and acid sphingomyelinase (SMPD1). This compound elevates intracellular sphingomyelin levels and modulates the distribution of sphingomyelin, disrupting signal transduction pathways in oncogenic K-Ras and H-Ras. Avicin G exhibits significant biological activity, including the reduction of ERK and Akt phosphorylation and alterations in lysosomal pH. Its applications extend to research on pancreatic ductal adenocarcinoma and non-small cell lung cancer. -
AP-1/NF-κB Activation Inhibitor
SPC 839 is an orally active inhibitor that targets AP-1 and NF-κB mediated transcriptional activation, demonstrating an IC50 of 0.008 μM. This compound is essential for studying pathways associated with inflammation, cancer progression, and cellular stress responses. Its potent inhibition of key transcription factors makes it a valuable tool for researchers investigating the role of AP-1 and NF-κB in various biological processes. -
NF-κB Inhibitor
Ganoderic acid H is a lanostane-type triterpene that functions as an NF-κB inhibitor. It effectively suppresses the growth and invasive behavior of breast cancer cells by inhibiting the activity of transcription factors AP-1 and NF-κB. This compound holds potential for research applications in cancer biology, particularly for studies focusing on the modulation of signaling pathways involved in tumor progression and metastasis. -
NF-κB/AP-1 Inhibitor
Glucocorticoid receptor modulator 1 is a selective non-steroidal modulator that targets the glucocorticoid receptor, exhibiting potent inhibition of NF-κB and AP-1 with IC50 values of 9 nM and 130 nM, respectively. This compound effectively reduces the expression of key inflammatory cytokines, including IL-6, IL-1β, and TNF-α. Additionally, it demonstrates potential in alleviating dermatitis in preclinical models, making it a valuable tool for research in inflammation and immune response. -
COX Inhibitor
Inulicin (1-O-Acetylbritannilactone) is a potent inhibitor of cyclooxygenase (COX) enzymes, specifically targeting COX-2 activity. This compound demonstrates significant biological activity by inhibiting lipopolysaccharide (LPS)-induced production of prostaglandin E2 (PGE2) as well as the expression of COX-2. Additionally, Inulicin suppresses NF-κB activation and its translocation, making it valuable for research applications related to inflammation and cancer. -
Syk Inhibitor
DBMB is a selective inhibitor of spleen tyrosine kinase (Syk) that effectively attenuates Syk kinase activity. Its mechanism of action involves the suppression of NF-κB signaling, leading to a decrease in the production of key inflammatory mediators, including nitric oxide (NO) and prostaglandin E2 (PGE2). DBMB is suitable for investigations focused on inflammatory diseases and elucidating the role of Syk in immune response pathways. -
NF-κB Inhibitor, GPx Inhibitor, HIV Replication Inhibitor
α-MSH (11-13) acetate is a selective melanocortin-1 receptor ligand that functions as an inhibitor of NF-κB, GPx activity, and HIV replication. It induces an acute elevation of intracellular calcium levels under certain costimulation or pathway inhibition conditions. This compound effectively suppresses TNF-α-induced NF-κB activation, inhibits colony formation of Staphylococcus aureus and Candida albicans, and demonstrates potential in the study of infections related to these pathogens, as well as in traumatic brain injury, corneal epithelial wounds, and inflammatory bowel disease research. -
ACAT Inhibitor
ACAT-IN-7 is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor. This compound effectively inhibits ACAT activity, resulting in altered lipid metabolism and subsequent reduction in cholesterol esterification. ACAT-IN-7 is of particular interest in research exploring its potential role in inflammatory processes, as it inhibits NF-κB mediated transcription, which is crucial for various cellular responses. -
ACAT Inhibitor
ACAT-IN-2 is a selective inhibitor of acyl-Coenzyme A:cholesterol acyltransferase (ACAT). This compound effectively inhibits the NF-κB mediated transcriptional process, making it a valuable tool for research in cholesterol metabolism and inflammatory pathways. ACAT-IN-2 is primarily utilized in studies investigating dyslipidemia and its associated diseases, contributing to a deeper understanding of lipid regulation and associated pathophysiology. -
ACAT Inhibitor
ACAT-IN-10 is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor that provides valuable insights into lipid metabolism. This compound is particularly useful in studying the regulation of cholesterol esters and their implications in various diseases, including atherosclerosis and metabolic disorders. Additionally, ACAT-IN-10 exhibits weak inhibition of NF-κB-mediated transcription, making it a potential tool for investigating inflammatory pathways. -
ACAT Inhibitor
ACAT-IN-4 hydrochloride is a selective acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor. It disrupts cholesterol esterification, leading to a reduction in lipid accumulation in cells. This compound has significant implications for research in atherosclerosis, inflammation, and lipid metabolism, particularly through its ability to inhibit NF-κB mediated transcription. -
ACAT Inhibitor
ACAT-IN-9 is a selective acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor that effectively disrupts the synthesis of cholesteryl esters. By inhibiting ACAT activity, ACAT-IN-9 also attenuates NF-κB mediated transcription, which plays a critical role in inflammation and immune responses. This compound is utilized in research focusing on lipid metabolism, cardiovascular diseases, and inflammation pathways. -
ACAT Inhibitor
ACAT-IN-4 is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor that effectively impedes ACAT activity. This compound has been shown to inhibit NF-κB mediated transcription, making it a valuable tool for studying cholesterol metabolism and inflammatory responses. ACAT-IN-4 is suitable for research applications focusing on lipid regulation, atherosclerosis, and other related cardiovascular conditions. -
ACAT Inhibitor
ACAT-IN-10 dihydrochloride is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor. This compound exhibits weak inhibition of NF-κB mediated transcription, highlighting its potential role in modulating inflammatory processes. It is primarily utilized in research focused on lipid metabolism and its implications in various diseases, including atherosclerosis and metabolic disorders. ACAT-IN-10 dihydrochloride serves as a valuable tool for investigating the biochemical pathways regulated by ACAT activity. -
ACAT Inhibitor
ACAT-IN-6 is a potent acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor. This compound effectively inhibits NF-κB mediated transcription, making it a valuable tool for studying lipid metabolism and inflammatory pathways. ACAT-IN-6 is useful in research applications focused on cholesterol homeostasis and related diseases. -
ACAT Inhibitor
ACAT-IN-3 is an inhibitor of acyl-Coenzyme A:cholesterol acyltransferase (ACAT), targeting the cholesterol esterification pathway. This compound effectively inhibits NF-κB-mediated transcription, making it a valuable tool in studying pathways associated with inflammation and lipid metabolism. Its application in research may help elucidate the role of ACAT in various disease models, particularly those related to atherosclerosis and other metabolic disorders. -
ACAT Inhibitor
ACAT-IN-5 is a selective inhibitor of acyl-Coenzyme A:cholesterol acyltransferase (ACAT), a key enzyme involved in cholesterol metabolism. By inhibiting ACAT activity, ACAT-IN-5 has been shown to modulate NF-κB mediated transcription, thereby influencing inflammatory pathways and lipid metabolism. This reagent is vital for research applications exploring cholesterol homeostasis, atherosclerosis, and related metabolic disorders. -
NF-κB/MAPKs Inhibitor
Tetrahydropiperine is a selective inhibitor of NF-κB and MAPKs, while simultaneously activating the PI3K/Akt/mTOR pathway. This compound effectively reduces the production of pro-inflammatory cytokines, including TNF-α, IL-6, and nitric oxide, by inhibiting the nuclear translocation of NF-κB and the phosphorylation of ERK, JNK, and p38 MAPKs. Additionally, Tetrahydropiperine mitigates excessive autophagy, offering neuroprotective benefits against oxidative damage. Its diverse biological activities make it valuable for research focused on inflammatory conditions, such as endotoxemia and arthritis, as well as neurological disorders, including ischemic stroke. -
Anti-oxidant, Aromatase Inhibitor, Anabolic Agent
5-Methyl-7-methoxyisoflavone is an orally active antioxidant that primarily functions as an aromatase inhibitor. This compound disrupts testosterone metabolic pathways, making it useful in various anabolic applications. It exhibits enhanced potency in increasing muscle mass and endurance compared to other anabolic agents. Additionally, 5-Methyl-7-methoxyisoflavone supports fat loss, contributes to the maintenance of low cholesterol levels, and aids in strengthening bone density. The compound also acts as an inhibitor of NF-κB, further expanding its potential therapeutic applications. -
11β-hydroxysteroid dehydrogenase 1 Inhibitor
Lunularin is a selective inhibitor of 11β-hydroxysteroid dehydrogenase 1, exhibiting an IC50 of 45.44 μM for human and 17.39 μM for rat enzymes. This compound has been shown to modulate gene expression by upregulating Sirt1 and Hmox1 in liver tissue, while also reducing food intake, body weight gain, and blood glucose levels in high-fat diet mice. Furthermore, Lunularin displays anti-cancer properties by inhibiting cell proliferation and colony formation in renal and colon cancer cell lines, along with suppression of LPS-induced NF-κB pathway activation. This reagent is valuable for research in obesity, cancer biology, inflammation, and metabolic disorders. -
ACAT Inhibitor
ACAT-IN-8 is a selective inhibitor of acyl-Coenzyme A:cholesterol acyltransferase (ACAT), a key enzyme involved in intracellular cholesterol esterification. By inhibiting ACAT, this compound modulates lipid metabolism and significantly impacts NF-κB mediated transcription. ACAT-IN-8 is useful for research applications related to cardiovascular diseases, metabolic disorders, and inflammation, providing insights into cholesterol-related pathways and their regulation. -
NF-κB Inhibitor
(R)-(+)-Anatabine is an NF-κB inhibitor that acts to lower amyloid-β (Aβ) production by preventing the β-cleavage of amyloid precursor protein (APP). As the less active R-enantiomer of Anatabine, it retains the ability to modulate α4β2 nAChR activity. This compound exhibits anti-inflammatory properties and is being investigated for its potential applications in the treatment of neurodegenerative disorders. -
Calcium Channel Inhibitor
Nothofagin is a dihydrochalcone that acts as a calcium channel inhibitor. By blocking calcium influx, it downregulates NF-κB translocation, providing a mechanism to modulate inflammatory responses. This compound exhibits antioxidant properties and has potential applications in research related to septic responses and vascular inflammation. -
MALT1 Inhibitor
Z-VRPR-FMK is an irreversible inhibitor of the MALT1 protein. It effectively inhibits the growth and invasion of diffuse large B-cell lymphoma by blocking MALT1-induced NF-κB activation and matrix metalloproteinase (MMP) expression. This makes Z-VRPR-FMK a valuable tool for research investigating the role of MALT1 in oncogenesis and therapeutic strategies targeting NF-κB pathways. -
MALT1 Inhibitor
MALT1-IN-5 is a potent inhibitor of the MALT1 protease, targeting the NF-κB signaling pathway. This compound has demonstrated significant biological activity in disrupting MALT1-dependent signaling processes. MALT1-IN-5 is primarily utilized in cancer research to investigate the role of MALT1 in tumorigenesis and its potential as a therapeutic target. -
MALT1 Inhibitor
NVS-MALT1 is an allosteric inhibitor of the MALT1 protein, disrupting its activity and providing a valuable tool for studying MALT1-mediated signaling pathways. This compound demonstrates the ability to modulate NF-κB activation and enhance apoptosis in cancer cells, making it relevant for research in oncology and immune response. It is particularly useful in investigations focusing on B-cell lymphoma and other MALT1-associated diseases. -
MALT1 Inhibitor
RGT-068A is a selective and orally bioavailable inhibitor of MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1). This compound demonstrates potent inhibitory activity against MALT1, which is essential for NF-κB signaling in various hematological malignancies and inflammatory diseases. RGT-068A serves as a valuable tool for research into therapeutic strategies targeting MALT1 in cancer and autoimmune disorders. -
NF-κB Inhibitor
SEMBL is a potent inhibitor of NF-κB, specifically targeting NF-κB-DNA binding to disrupt its transcriptional activity. This compound effectively reduces the secretion of NF-κB-dependent inflammatory cytokines and diminishes cancer cell migration and invasion by decreasing matrix metalloproteinase (MMP) expression. SEMBL is valuable for research in anticancer therapies and the study of inflammation-related pathways. -
CHI3L1 Inhibitor
CHI3L1-IN-5 is a selective inhibitor of CHI3L1, exhibiting a KD value of 6 μM. This compound enhances astrocytic clearance by rejuvenating lysosomal function and promoting Aβ uptake, while simultaneously mitigating neuroinflammation through inhibition of the NF-κB pathway. CHI3L1-IN-5 is valuable for investigating its potential therapeutic applications in Alzheimer's disease research. -
NF-κB Nuclear Accumulation Inhibitor
Cyclo(his-pro) TFA is a cyclic dipeptide that functions as an NF-κB nuclear accumulation inhibitor. This compound is capable of crossing the blood-brain barrier, making it valuable for studying its effects on various inflammatory and stress-related pathways. Its ability to modulate NF-κB activity supports research in neuroinflammation and other related conditions. -
IKKα Inhibitor
BAY32-5915 is a selective inhibitor of IKKα, exhibiting an IC50 value of 60 nM. This compound effectively prevents the activation of NF-κB without interfering with Doxorubicin-induced pathways. It is valuable for research in inflammation and cancer, providing insights into NF-κB signaling modulation. -
IKK/NF-κB Inhibitor
NF-κB-IN-1 is a selective inhibitor of the IκB kinase (IKK) and functions primarily through the inhibition of NF-κB signaling. This compound effectively blocks the activation of NF-κB, demonstrating potent anti-cancer activity by reducing cell viability in lung cancer cells. Additionally, NF-κB-IN-1 significantly diminishes the clonogenic potential of A549 cells, making it a valuable tool for research on cancer therapeutics targeting NF-κB pathways. -
IKK Inhibitor
SU1261 is a potent inhibitor of IKK, displaying Ki values of 10 nM for IKKα and 680 nM for IKKβ. This compound effectively inhibits non-canonical NF-κB signaling pathways, making it a valuable tool for studying the role of IKK in various cellular processes. Its application in research, particularly in osteosarcoma cell models such as U2OS, can provide insights into inflammatory responses and oncogenic signaling mechanisms. -
IKK/NF-κB Inhibitor
SR12343 is an IKK/NF-κB inhibitor that acts as a mimetic of the NF-κB essential modulator (NEMO)-binding domain. It effectively disrupts the interaction between IKKβ and NEMO, leading to inhibition of TNF-α- and LPS-induced NF-κB activation, with an IC50 of 37.02 μM for TNF-α-mediated pathways. SR12343 has been shown to reduce LPS-induced acute pulmonary inflammation in murine models, making it valuable for research into inflammatory and degenerative diseases. -
IKKβ Inhibitor
BOT-64 is a selective IκB kinase β (IKKβ) inhibitor with an IC50 value of 1 µM. This compound effectively inhibits lipopolysaccharide-induced activation of nuclear factor-κB (NF-κB) and the subsequent transcription of NF-κB-regulated inflammatory genes. BOT-64 is valuable for research into inflammatory pathways and NF-κB signaling, providing insights into potential therapeutic strategies for inflammatory diseases. -
ikkβ Inhibitor
IKKβ-IN-4 is a selective inhibitor of IkappaB kinase-β (IKKβ), with an IC50 value of 1.9 μM. IKKβ plays a crucial role in the NF-κB signaling pathway, which is implicated in various diseases, including inflammation and cancer. This compound is utilized in research to study the modulation of NF-κB activity and its potential therapeutic applications in related disease models. -
IKK2 Inhibitor
IKK2-IN-3 is a selective inhibitor of IKK2, demonstrating a potent inhibitory effect with an IC50 value of 0.075 μM. This compound effectively disrupts the NF-κB signaling pathway, impacting various cellular processes such as inflammation and immune response. IKK2-IN-3 is suitable for research applications involving the modulation of IKK2 activity in disease models and studying the role of NF-κB in cellular signaling. -
IKK2 Inhibitor
LY2409881 is a selective inhibitor of IκB kinase β (IKK2), demonstrating potent inhibition with an IC50 of 30 nM. This compound is primarily used in research for its ability to modulate the NF-κB signaling pathway, making it relevant for studying inflammation, cancer, and autoimmune diseases. Researchers utilize LY2409881 to explore its therapeutic potential in various disease models and to investigate the role of IKK2 in cellular processes. -
IκB Kinase-2 Inhibitor
PS-1145 dihydrochloride is a selective inhibitor of IκB kinase-2, exhibiting an IC50 value of 88 nM. This compound effectively inhibits the phosphorylation of IκB kinase, thereby suppressing NF-κB activity. PS-1145 dihydrochloride is utilized in research applications targeting inflammatory responses and cancer biology. -
IKK2 Inhibitor
IKK-IN-4 is a selective inhibitor of IkappaB kinase 2 (IKKβ), exhibiting an IC50 of 45 nM for IKKβ and 650 nM for IKKα. This compound is instrumental in research focusing on the NF-κB signaling pathway and its regulation, providing insights into inflammation, cancer, and other diseases linked to IKK activity. IKK-IN-4 serves as a valuable tool for studying IKKβ-mediated signaling mechanisms and potential therapeutic interventions. -
IKK Inhibitor
(E/Z)-HOIPIN-1 is a selective inhibitor of the linear ubiquitin chain assembly complex (LUBAC), targeting the IκB kinase (IKK) pathway. With an IC50 value greater than 2.8 μM, this compound effectively inhibits LUBAC-mediated NF-κB activation. Its potential applications include studies of inflammatory responses, cancer biology, and the modulation of immune signaling pathways. -
IKKβ Inhibitor
MLN-0415 is an inhibitor of IKKβ, a key regulator in the NF-κB signaling pathway. This compound exhibits significant anti-inflammatory activity and is instrumental in researching conditions such as arthritis and other inflammatory diseases. MLN-0415 facilitates the exploration of therapeutic strategies targeting the modulation of inflammatory responses. -
IKKβ Inhibitor
1-Dehydro-[10]-gingerdione functions as a selective inhibitor of IKKβ by targeting its activation loop, leading to the disruption of IKKβ-mediated phosphorylation of IκBα in macrophages stimulated with various agonists. This compound effectively inhibits LPS-induced NF-κB transcriptional activity. 1-Dehydro-[10]-gingerdione holds promise for research into NF-κB-related inflammation and autoimmune disorders. -
IkappaB kinase inhibitor
CGA-JK3 is an ATP-competitive inhibitor of IκB kinase (IKKβ), effectively hindering its kinase activity. This compound inhibits the phosphorylation of IκBα in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells, demonstrating its potential in studying inflammatory signaling pathways. CGA-JK3 is useful for researchers investigating the modulation of NF-κB signaling and related biological processes. -
IKKα/β Inhibitor
GTCpFE is a selective inhibitor of IKKα/β, functioning within the NF-κB signaling pathway. This compound exhibits significant anti-inflammatory properties by preventing the nuclear translocation of the p65 subunit of NF-κB. Additionally, GTCpFE demonstrates targeted anti-cancer stem-like cell activity by impairing mammosphere formation and reducing the CD44+ CD24- immunophenotype associated with aggressive breast cancer. Its dual mechanism positions GTCpFE as a promising agent for both inflammation and cancer research. -
NIK Inhibitor
B022 is a selective inhibitor of NF-κB-inducing kinase (NIK) with a Ki of 4.2 nM and an IC50 of 15.1 nM. This compound exhibits protective effects against liver inflammation, oxidative stress, and injury caused by toxins. Additionally, B022 features an alkyne group, enabling its use in click chemistry applications, specifically for copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules.
